Henlius and DP Technology Announce Strategic Collaboration on AI-Driven Drug Discovery

Recently, Shanghai Henlius Biotech, Inc. (2696.HK) and DP Technology announced a strategic partnership in AI-assisted drug discovery, aiming to jointly advance the new drug development process by combining artificial intelligence with physical modeling. This collaboration will leverage DP Technology's technical expertise and project experience in the AI for Science domain, along with the expert knowledge of both parties in drug discovery and AI computing.Biological Drug Antibody/ADC,Provide new ideas and methods for the research and development of small molecule drugs for difficult drug targets.

• In the field of cancer treatment, there is significant development potential in targeting points. The industry's research and development on collaborative targets is still in the exploratory stage, based onAI for Science DevelopedRiDYMO®  High QualityHit Discovery and Optimization Platform, from0To1Design, aimed at developing potentialfirst-in-class（FIC) small molecule candidate drug.
• In ADCIn terms of drugs, based onRiDYMO® The platform further integrates DP Technology.“Based on AI+ First-Principles Calculation-Driven Linker Method for Predicting Cleavage Sites”，Continuously explore and collaborate to develop innovative, highly efficient, and differentiated ADC New drug.
• In terms of biologics, based onHermite® Drug Design Platform, Breaking Traditional Limits and IntegratingAI Conduct antibody discovery and optimization through physical calculations,Optimize drug-like properties, expand the number of lead antibodies, and provide more options for the early stage of antibody discovery.。

RiDYMO® is a high-quality Hit discovery and optimization platform developed by DP Technology based on AI for Science. Relying on the independently developed Hermite® computational drug design software, it aims to unlock the kinetic mechanisms of difficult-to-drug targets through innovative artificial intelligence, physical algorithms, and high-throughput experiments, exploring a broader chemical space of small molecules, macrocyclic molecules, and cyclic peptides. The platform has unique advantages in the design of orally available macrocyclic molecules, and when combined with parallel synthesis, can rapidly deliver novel drug candidate compounds. One of its core algorithms, Reinforced Dynamics (RiD), achieves nearly a hundredfold improvement in molecular simulation sampling efficiency. By fully leveraging the high-dimensional representation capabilities of neural networks, RiD effectively captures dynamic conformational changes in complex biomolecular systems. The RiDYMO® platform has been successfully applied to multiple projects, including the design of c-Myc small molecules, GPX4 small molecules, and β-catenin cyclic peptides, fully demonstrating its strong potential in innovative drug discovery.

Shanghai Henlius Biotech, Inc. (2696.HK) is an international innovative biopharmaceutical company dedicated to providing affordable high-quality biologics for patients worldwide. Its products cover areas such as oncology, autoimmune diseases, and ophthalmic diseases. Six of its products have been approved for marketing in China, three internationally, with four marketing applications accepted by the Chinese NMPA, U.S. FDA, and EU EMA respectively. Since its establishment in 2010, Henlius has built an integrated biopharmaceutical platform with efficient and innovative core competencies spanning the entire industry chain from R&D to production and commercial operations. The company has established a robust global innovation center, adhering to international Good Manufacturing Practice (GMP) standards in production and quality control while continuously strengthening its integrated comprehensive production platform. Notably, the company’s commercial production facilities have successively obtained GMP certifications from China, the EU, and the U.S.

Shanghai Henlius Biotech, Inc. has proactively laid out a diversified and high-quality product pipeline covering more than 50 molecules, while comprehensively advancing tumor immunotherapy combination treatments based on its proprietary anti-PD-1 monoclonal antibody drug, HANSIZHUANG® (serplulimab). To date, the company's commercially approved products include China’s first biosimilar Hanlikang® (rituximab), self-developed biosimilar antibodies approved in China, the U.S., and Europe, Hanquyou® (trastuzumab, U.S. trade name: HERCESSI™, European trade name: Zercepac®), Handayuan® (adalimumab), Hanbeitai® (bevacizumab), the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer, HANSIZHUANG® (serplulimab), and Hannaijia® (neratinib). The company is also simultaneously conducting over 30 clinical trials across 16 products globally, with out-licensing coverage spanning mainstream biopharmaceutical markets in Europe and the U.S., as well as numerous emerging markets.